Navigation Links
Lineagen Announces $3.5 Million Series C Round and Close of Series B Financing
Date:12/18/2013

SALT LAKE CITY, Dec. 18, 2013 /PRNewswire/ -- Lineagen, Inc., an innovative molecular diagnostics company focused on complex, genetically linked disorders, announced today the Company has completed a $3.5 million series C round of financing, including $2.6 million in equity capital and $0.9 million in convertible senior subordinated notes.  The financing was led by existing investors Signal Peak Ventures and Sanderling Ventures, with the participation of current investors PrairieGold Venture Partners and Mesa Verde Venture Partners and new investors Archipel Capital, University Venture Fund, Hatteras Funds, and KickStart Seed Fund.  Lineagen also announced the Company has received multiple term sheets for multi-million dollar senior secured debt facilities, one of which the Company intends to close as part of this Series C financing.  Additionally, Lineagen announced the conversion of $12.6 million in outstanding promissory notes into shares of Series B preferred stock.

Lineagen is a leader in providing physicians and patients with a fully integrated genetic testing, counseling, and developmental screening service to aid in the early diagnostic evaluation of individuals with ASD and other disorders of childhood development.  Based on current reimbursement rates, sales, and favorable gross margins of Lineagen's customized proprietary commercial offering, FirstStepDx PLUS, and pursuant to the use of net proceeds of the Series C funding and anticipated loan facility, the Company expects it will accelerate the time to profitability to the first half of 2014.

Lineagen's Chief Executive Officer Michael S. Paul, Ph.D., said, "As a science-driven company, our paramount dedication is to the clinical community and to the families we serve.  We now provide our FirstStepDx PLUS services to over 400 pediatricians across the country, and we have agreements with payors and provider networks to provide access to FirstStepDx PLUS to approximately 70 million covered lives.  Lineagen has consistently attained high levels of reimbursement, with increased reimbursement levels being seen under the new reimbursement codes, attesting to the significant clinical benefit of our commercial offerings."

Dr. Paul continued, "We are grateful to the communities we serve and to our investors who have continued to support our programs and build our commercial presence and brand in the market. In 2014, we will seek to close an additional tranche in our Series C financing – up to $7 to $7.5 million – which we anticipate would allow us to launch new commercial offerings, including NextStepDx PLUS, a customized, proprietary next generation sequencing-based reflex test that is expected to significantly add to the current diagnostic yield of FirstStepDx PLUS; expand our sales team's ability to reach specialist physicians, and seek to ensure additional payer coverage. It's an exciting time for the Company, we are pleased with Lineagen's position in the market and achievements, and we look forward to further progress of our programs."

About FirstStepDx PLUS

Lineagen's FirstStepDx PLUS and related autism-risk screening services (www.mchat.org) have been developed with the specific intention of helping physicians, patients, and families navigate the diagnostic evaluation "odyssey" of individuals with autism spectrum disorders (ASDs) and other disorders of childhood development early and more efficiently.  FirstStepDx PLUS includes genetic counseling, the most advanced, customized chromosomal microarray analysis (CMA) clinically available, and a detailed, personalized report created specifically for each individual's case.  FirstStepDx PLUS is specifically designed to help parents, physicians, and other healthcare providers significantly shorten the time to clinical action, allowing access to proven clinical management and treatment approaches as early as possible.  The customized and proprietary CMA platform incorporated into FirstStepDx PLUS was developed in collaboration with Affymetrix under the Powered by Affymetrix program.  Further, Lineagen's FirstStepDx PLUS incorporates novel validated genetic variants recently featured in the publication of results of a 9,000-person genetic study by researchers affiliated with The Children's Hospital of Philadelphia (CHOP), the University of Utah, Golden Helix, Inc, and Lineagen (http://dx.plos.org/10.1371/journal.pone.0052239).

The FirstStepDx PLUS genetic test was the first such test to be available as a fast and painless cheek swab (FirstStepDx PLUS Buccal), eliminating the need for a blood draw.  For more information about FirstStepDx PLUS, please call Lineagen at 888-888-OPEN (888-888-6736) or visit www.firststepdxplus.com.

About Lineagen

Based in Salt Lake City, Utah, Lineagen's mission is to accelerate and enhance the diagnostic evaluation of medical conditions so that the best possible outcomes can be achieved for patients and their families.  Our first commercial offering, FirstStepDx PLUS, provide physicians with a fully integrated genetic testing, counseling, and developmental screening service to aid in the diagnostic evaluation of individuals with ASD or other forms of developmental delay.  In addition to our deep commitment to ASD and developmental delay, we have ongoing scientific programs in the areas of multiple sclerosis (MS) and chronic obstructive pulmonary disease (COPD).

For additional information, please visit www.lineagen.com.

Contacts:

Lineagen contact
Dr. Michael Paul
801-931-6200

Burns McClellan, on behalf of Lineagen
Justin Jackson

212-213-0006
jjackson@burnsmc.com


'/>"/>
SOURCE Lineagen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol
2. Asmacure Announces Clinical Update for ASM-024 DPI in Two Phase 2 Trials
3. China Cord Blood Corporation Announces Results of 2013 Annual General Meeting
4. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
5. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer
6. Pittcon Announces the 2014 Technical Program
7. AudioNotch Tinnitus Treatment Announces Holiday Sale
8. Spotlight Innovation, Inc. Announces Name Change and Closing of Merger
9. DryLet, LLC Announces Investment from Ronald A. Chisholm Limited to Support Growth and Expansion
10. Synthetic Biologics Announces Proposed Public Offering of Common Stock
11. Endo Health Solutions Announces Proposed Private Offering of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts ... they believe could be a new and helpful biomarker for malignant pleural mesothelioma. ... here to read it now. , Biomarkers are components in the blood, ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
Breaking Biology Technology:
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):